CBD shows early promise for neurodevelopmental disorders in children

Emerging clinical evidence suggests cannabidiol may safely improve symptoms of autism spectrum disorder, intellectual disability, tics, and ADHD in children, though research remains early.

Dias-de Freitas, F et al.·Revista de neurologia·2022·Preliminary EvidenceReview
RTHC-03806ReviewPreliminary Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

CBD modulates the endocannabinoid system in developing brains through multiple mechanisms and appears to have anxiolytic, antipsychotic, and neuroprotective properties. Clinical evidence suggests early CBD treatment could improve common symptoms in neurodevelopmental disorders including social interaction deficits, anxiety, hyperactivity, and sleep problems.

Key Numbers

Review covers four neurodevelopmental disorders: intellectual disability, autism spectrum disorder, tics, and ADHD. CBD described as having a "relatively high toxicity limit."

How They Did This

Literature review of clinical and pre-clinical studies on cannabinoid use in pediatric neurodevelopmental disorders, with attention to safety and efficacy.

Why This Research Matters

Neurodevelopmental disorders affect millions of children and current medications often have significant side effects. CBD offers a potential alternative with a relatively high safety threshold.

The Bigger Picture

The pathophysiology of neurodevelopmental disorders remains only partially understood, making targeted pharmacological treatment difficult. CBD's broad neuromodulatory effects may address multiple symptom domains simultaneously.

What This Study Doesn't Tell Us

Most evidence is preliminary. Limited controlled trials in pediatric populations. Long-term effects of CBD on developing brains need more study.

Questions This Raises

  • ?What are the optimal CBD doses for different neurodevelopmental conditions in children?
  • ?How does long-term CBD use affect brain development?

Trust & Context

Key Stat:
Evidence spans autism, intellectual disability, tics, and ADHD
Evidence Grade:
Narrative review drawing on limited clinical studies and preclinical data. Most evidence is early-stage.
Study Age:
Published in 2022.
Original Title:
The role of cannabinoids in neurodevelopmental disorders of children and adolescents.
Published In:
Revista de neurologia, 75(7), 189-197 (2022)
Database ID:
RTHC-03806

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Which neurodevelopmental disorders showed the most promise?

Autism spectrum disorder had the most emerging evidence, with studies suggesting CBD may improve social interaction, anxiety, hyperactivity, and sleep problems.

Is CBD safe for children?

The review notes CBD has a "relatively high toxicity limit," but emphasizes that long-term safety data in developing brains is still limited and more research is needed.

Read More on RethinkTHC

Cite This Study

RTHC-03806·https://rethinkthc.com/research/RTHC-03806

APA

Dias-de Freitas, F; Pimenta, S; Soares, S; Gonzaga, D; Vaz-Matos, I; Prior, C. (2022). The role of cannabinoids in neurodevelopmental disorders of children and adolescents.. Revista de neurologia, 75(7), 189-197. https://doi.org/10.33588/rn.7507.2022123

MLA

Dias-de Freitas, F, et al. "The role of cannabinoids in neurodevelopmental disorders of children and adolescents.." Revista de neurologia, 2022. https://doi.org/10.33588/rn.7507.2022123

RethinkTHC

RethinkTHC Research Database. "The role of cannabinoids in neurodevelopmental disorders of ..." RTHC-03806. Retrieved from https://rethinkthc.com/research/dias-de-2022-the-role-of-cannabinoids

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.